02/17/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Johnson & Johnson's DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed patients with multiple myeloma who are transplant ineligible

 

More Info